https://thamesuro.com/podcast/ en-gb © Thames Uro Limited The FRCS (Urol) syllabus in bite-sized episodes, one topic at a time, each about fifteen minutes. Written by a urology registrar sitting the exam and grounded in current EAU, NICE and BAUS guidance, so what you hear is what the exam actually rewards. Revise on the commute, on the ward round, or in the last three days before the paper. These episodes are free. The full library of 30+ episodes, the original SBA question bank, the guideline-cited crib sheets and the live AI viva examiner are at thamesuro.com. The FRCS (Urol) syllabus in bite-sized episodes, one topic at a time, each about fifteen minutes. Written by a urology registrar sitting the exam and grounded in current EAU, NICE and BAUS guidance, so what you hear is what the exam actually rewards. Revise on the commute, on the ward round, or in the last three days before the paper. These episodes are free. The full library of 30+ episodes, the original SBA question bank, the guideline-cited crib sheets and the live AI viva examiner are at thamesuro.com. The FRCS (Urol) syllabus, one topic at a time Thames Uro Thames Uro info@thamesuro.com false episodic https://thamesuro.com/podcast/cover.f808f6b8.jpg https://thamesuro.com/podcast/ Tue, 29 Sep 2026 16:28:15 +0000 The best place to begin: the highest-yield topic in the exam, at the pace the rest of the series runs. What the screening trials really show and why they only look contradictory, the MRI-first pathway and biparametric scanning, why the biopsy left the operating theatre, the T2 change people miss, who actually needs staging imaging, why three surgery-versus-monitoring trials disagree, when a benign biopsy is not reassuring, and the two recurrence definitions you must not mix up. The best place to begin: the highest-yield topic in the exam, at the pace the rest of the series runs. What the screening trials really show and why they only look contradictory, the MRI-first pathway and biparametric scanning, why the biopsy left the operating theatre, the T2 change people miss, who actually needs staging imaging, why three surgery-versus-monitoring trials disagree, when a benign biopsy is not reassuring, and the two recurrence definitions you must not mix up. thamesuro-frcs15-001-prostate-cancer Sun, 20 Sep 2026 08:00:00 +0100 17:46 7 full false https://thamesuro.com/podcast/ The haematuria pathway now it is risk-stratified, why the chest scan you were taught to order has largely gone, where NICE and the EAU genuinely disagree on follow-up, what counts as BCG failure and what you can offer when it happens, muscle-invasive disease including the chemotherapy substitution that costs a cure, first-line metastatic treatment, who needs a second resection, and why the upper tract behaves differently. The haematuria pathway now it is risk-stratified, why the chest scan you were taught to order has largely gone, where NICE and the EAU genuinely disagree on follow-up, what counts as BCG failure and what you can offer when it happens, muscle-invasive disease including the chemotherapy substitution that costs a cure, first-line metastatic treatment, who needs a second resection, and why the upper tract behaves differently. thamesuro-frcs15-002-bladder-utuc Sat, 19 Sep 2026 08:00:00 +0100 17:07 6 full false https://thamesuro.com/podcast/ Choosing by the patient rather than the tumour in the small renal mass, what the Bosniak system is actually measuring and where surgery overtreats, when a biopsy helps and the scan that reads mitochondria, the one piece of biology that explains why the drugs work, why removing the kidney in metastatic disease is no longer automatic, and a safe approach to the adrenal incidentaloma. Choosing by the patient rather than the tumour in the small renal mass, what the Bosniak system is actually measuring and where surgery overtreats, when a biopsy helps and the scan that reads mitochondria, the one piece of biology that explains why the drugs work, why removing the kidney in metastatic disease is no longer automatic, and a safe approach to the adrenal incidentaloma. thamesuro-frcs15-003-kidney-adrenal Fri, 18 Sep 2026 08:00:00 +0100 15:30 5 full false https://thamesuro.com/podcast/ The infected obstructed kidney and the stent you should not place, why five to six millimetres decides so much, why you should not believe a patient who says the stone has passed, what the expulsive therapy evidence really says, what PUrE changed for lower pole stones, how the rules reverse in pregnancy, why restricting dietary calcium makes things worse, and the two stones where chemistry is the treatment. The infected obstructed kidney and the stent you should not place, why five to six millimetres decides so much, why you should not believe a patient who says the stone has passed, what the expulsive therapy evidence really says, what PUrE changed for lower pole stones, how the rules reverse in pregnancy, why restricting dietary calcium makes things worse, and the two stones where chemistry is the treatment. thamesuro-frcs15-004-stone-disease Thu, 17 Sep 2026 08:00:00 +0100 16:35 4 full false https://thamesuro.com/podcast/ The impalpable lesion on a scan and whether he needs to lose a testis to find out, tumour markers that mislead in both directions, fertility and the retrieval option people forget, how the prognostic groups actually work, stage one and the surveillance-or-treat decision, what to do with what is left after chemotherapy, the lumps that are not germ cell tumours, and why a node dissection costs ejaculation. The impalpable lesion on a scan and whether he needs to lose a testis to find out, tumour markers that mislead in both directions, fertility and the retrieval option people forget, how the prognostic groups actually work, stage one and the surveillance-or-treat decision, what to do with what is left after chemotherapy, the lumps that are not germ cell tumours, and why a node dissection costs ejaculation. thamesuro-frcs15-005-testicular-cancer Wed, 16 Sep 2026 08:00:00 +0100 14:58 3 full false https://thamesuro.com/podcast/ What you want at the first appointment and what you do not, how a flow meter works and how to read the trace, what the flow number really tells you about obstruction, the medical therapy trials worth quoting, the surgical trade-off between keeping ejaculation and how long the operation lasts, the reoperation rates that settle it, and the man in chronic retention where the question is when, not whether. What you want at the first appointment and what you do not, how a flow meter works and how to read the trace, what the flow number really tells you about obstruction, the medical therapy trials worth quoting, the surgical trade-off between keeping ejaculation and how long the operation lasts, the reoperation rates that settle it, and the man in chronic retention where the question is when, not whether. thamesuro-frcs15-006-bph-luts Tue, 15 Sep 2026 08:00:00 +0100 16:55 2 full false https://thamesuro.com/podcast/ What drives management before any grading, how to answer on the AAST scale and what the 2025 revision changed, what you are actually trying to achieve when you open a bleeding kidney, ureteric injury and its damage-control option, the pelvic fracture patterns that should make you look at the bladder, and the urethral and genital injuries that turn up in the viva as much as the paper. What drives management before any grading, how to answer on the AAST scale and what the 2025 revision changed, what you are actually trying to achieve when you open a bleeding kidney, ureteric injury and its damage-control option, the pelvic fracture patterns that should make you look at the bladder, and the urethral and genital injuries that turn up in the viva as much as the paper. thamesuro-frcs15-007-trauma Mon, 14 Sep 2026 08:00:00 +0100 16:22 1 full false https://thamesuro.com/podcast/